- Green Thumb Industries (OTC: GTBIF) is set to release its anticipated quarterly earnings report, with Wall Street analysts projecting $0.02 earnings per share (EPS) and $297.64 million in revenue.
- A significant federal policy shift, involving the rescheduling of medical marijuana to Schedule III, is poised to deliver a “billion-dollar tax cut” for the broader cannabis industry, benefiting multi-state operators (MSOs) like Green Thumb Industries.
- The company demonstrates robust financial health, highlighted by a trailing price-to-earnings (P/E) ratio of 16.39, a price-to-sales (P/S) ratio of 1.62, a low debt-to-equity ratio of 0.27, and a strong current ratio of 1.55.
Green Thumb Industries (OTC: GTBIF) is a leading national cannabis company that owns and operates RISE Dispensaries. The company is a multi-state operator (MSO) in the dynamic U.S. cannabis market, competing with other major players like Curaleaf Holdings (OTC: CURLF) and Trulieve Cannabis (OTC: TCNNF). Green Thumb Industries is scheduled to release its anticipated quarterly earnings report on Wednesday, May 6, 2026.
Ahead of the report, Wall Street analysts are estimating earnings of approximately $0.02 per share. The revenue projection for the quarter is $297.64 million. These figures are being watched closely, especially following a significant federal policy shift that is creating substantial changes throughout the evolving cannabis sector.
This shift involves the U.S. government’s decision to reschedule medical marijuana to Schedule III from Schedule I. As highlighted by The Motley Fool, this historic medical marijuana rescheduling is a huge milestone. It allows companies like Green Thumb Industries to claim more business expenses, which could result in a “billion-dollar tax cut” for the broader cannabis industry, as noted by MarketBeat.
Looking at its key financial metrics, Green Thumb Industries has a trailing price-to-earnings (P/E) ratio of 16.39. This ratio suggests investors are willing to pay $16.39 for every dollar of the company’s earnings. Its price-to-sales (P/S) ratio is 1.62, indicating the stock’s price relative to its revenues, offering investor insights into stock valuation.
From a financial health perspective, the company shows a debt-to-equity ratio of 0.27. This low ratio suggests the company uses less debt to finance its assets compared to equity. Furthermore, its current ratio of 1.55 shows it has $1.55 in short-term assets for every $1 of short-term liabilities, indicating a strong liquidity position.
